EPO to protect renal function after cardiac surgery. EPRICS. A phase II double blind randomized controlled study. - EPRICS

• Conditions: Renal function after cardiac surgery; MedDRA version: 13.1Level: HLGTClassification code 10011082Term: Coronary artery disordersSystem Organ Class: 10007541 - Cardiac disorders; Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

• Registration Number: EUCTR2011-001673-70-SE
• Lead Sponsor: Skånes Universitetssjukhus

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-06-10
• Last Update Posted: 29 April 2013

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Patients planed for Coronary Artery Bypass Grafting (CABG).
Non-emergent CABG, eGFR-CyC< 60 ml/min and
written consent to participate

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 20
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 50

Exclusion Criteria

Uncontrolled hypertension, pregnancy or fertile woman (less than 50 years old), Epo treatment within 4 weeks, eGFR-CyC<15 or dialysis, known malignancy and Off-pump surgery

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified